European Guideline (EuroGuiDerm) on atopic eczema: Living update
- PMID: 40317496
- PMCID: PMC12376260
- DOI: 10.1111/jdv.20639
European Guideline (EuroGuiDerm) on atopic eczema: Living update
Abstract
The evidence- and consensus-based living guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. The original EuroGuiDerm Guideline on atopic eczema was published in June 2022. Since then, the part of the guideline dealing with systemic therapy has been updated twice. This paper summarizes the results of the second update. Twenty-eight experts (including clinicians and patient representatives) from 12 European countries participated. The updated guideline provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab and tralokinumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib and upadacitinib). Additionally, the updated guidelines address considerations for paediatric, adolescent, pregnant and breastfeeding patients. For all other aspects, please refer to the 2022 version.
© 2025 The Author(s). Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Conflict of interest statement
This is a summary of the second update of the EuroGuiDerm Guideline on atopic eczema. For the complete guideline, methods report (including COI disclosures) and evidence report, see
Figures
References
-
- Kaminski‐Hartenthaler A, Meerpohl JJ, Gartlehner G, Kien C, Langer G, Wipplinger J, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations [GRADE Leitlinien: 14. Von der Evidenz zur Empfehlung: Die Bedeutung und Darstellung von Empfehlungen]. Z Evid Fortbild Qual Gesundhwes. 2014;108(7):413–420. - PubMed
-
- Drucker AM, Flohr C, Ellis AG, Prieto‐Merino D, Rochwerg B, Bohdanowicz M, et al. Systemic immunomodulatory treatments for atopic dermatitis: a living systematic review and network meta‐analysis. 2024. Available from: https://eczematherapies.com/research/. Accessed 18 July 2024.
-
- Wollenberg A, Christen‐Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin‐Weller M, et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. - PubMed
